NUFLOR GOLD™ should be administered once by subcutaneous injection at a dose rate of 40 mg florfenicol/kg body weight (6 mL/100 lb). Do not administer more than 15 mL at each site. The injection should be given only in the neck. Injection sites other than the neck have not been evaluated. NUFLOR GOLD™ Dosage Guide ANIMAL WEIGHT (lb) DOSAGE (mL) 100 6.0 Recommended Injection Location: 200 12.0 300 18.0 400 24.0 500...
Store between 2°-30°C (36°-86°F). Use within 28 days of first use. Refrigeration is not required. The solution is light yellow to straw colored. Color does not affect potency.
Injectable Solution, An Antimicrobial
300 mg/mL
For subcutaneous use in beef and non-lactating dairy cattle only
Not for use in female dairy cattle 20 months of age or older or in calves to be processed for veal
PRODUCT
INFORMATION
Federal law restricts this drug to use by or on the order of a licensed veterinarian.
NUFLOR GOLD™ is an injectable solution of the synthetic antibiotic florfenicol. Each milliliter of sterile NUFLOR GOLD™ contains 300 mg of florfenicol, 300 mg of 2-pyrrolidone, and triacetin qs.
NUFLOR GOLD™ is indicated for treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis in beef and non-lactating dairy cattle.
NUFLOR GOLD™ should be administered once by subcutaneous injection at a dose rate of 40 mg florfenicol/kg body weight (6 mL/100 lb). Do not administer more than 15 mL at each site. The injection should be given only in the neck. Injection sites other than the neck have not been evaluated.
| NUFLOR GOLD™ Dosage Guide | ||
| ANIMAL WEIGHT (lb) | DOSAGE (mL) | |
| 100 | 6.0 | Recommended Injection Location: |
| 200 | 12.0 | |
| 300 | 18.0 | |
| 400 | 24.0 | |
| 500 | 30.0 | |
| 600 | 36.0 | |
| 700 | 42.0 | |
| 800 | 48.0 | |
| 900 | 54.0 | |
| 1000 | 60.0 | |
Do not use in animals that have shown hypersensitivity to florfenicol.
NOT FOR HUMAN USE. KEEP OUT OF REACH OF CHILDREN. This product contains materials that can be irritating to skin and eyes. Avoid direct contact with skin, eyes, and clothing. In case of accidental eye exposure, flush with water for 15 minutes. In case of accidental skin exposure, wash with soap and water. Remove contaminated clothing. Consult a physician if irritation persists. Accidental injection of this product may cause local irritation. Consult a physician immediately. The Material Safety Data Sheet (MSDS) contains more detailed occupational safety information.
For customer service, to report suspected adverse reactions, or to obtain a copy of the MSDS, call 1-800-211-3573.
Not for use in animals intended for breeding purposes. The effects of florfenicol on bovine reproductive performance, pregnancy, and lactation have not been determined. Toxicity studies in dogs, rats, and mice have associated the use of florfenicol with testicular degeneration and atrophy.
Subcutaneous injection in cattle can cause a transient local tissue reaction that may result in trim loss of edible tissue at slaughter.
Animals intended for human consumption must not be slaughtered within 44 days of treatment. Do not use in female dairy cattle 20 months of age or older. Use of florfenicol in this class of cattle may cause milk residues. A withdrawal period has not been established in pre-ruminating calves. Do not use in calves to be processed for veal.
Transient inappetence, diarrhea, decreased water consumption, and injection site swelling have been associated with the use of florfenicol in cattle. In addition, anaphylaxis and collapse have been reported post-approval with the use of another formulation of florfenicol in cattle.
The pharmacokinetic disposition of NUFLOR GOLD™ was evaluated in feeder calves following a single subcutaneous injection at a dose rate of 40 mg florfenicol/kg body weight. Administration of NUFLOR GOLD™ resulted in florfenicol plasma concentrations of 2 µg (mcg)/mL within two hours of injection.
| Cmax
(µg/mL) | Tmax
(hr) | AUClast
(µg*hr/mL) | T½ (hr) | |
|---|---|---|---|---|
| Cmax: Maximum observed plasma concentration Tmax: Time at which Cmax was observed AUClast: Area under the plasma-concentration-time curve from time zero to the last quantifiable concentration that is equal to or greater than the limit of quantification of the validated analytical method T½: Terminal elimination half-life % CV: Percent coefficient of variance | ||||
| n | 24 | 24 | 24 | 23* |
| Mean | 5.93 | 5† | 150 | 37.7 |
| % CV | 38.3 | 2-12† | 20.9 | 27.3 |
* T½ value could not be accurately estimated for one calf
† Tmax is presented as the median value or range of observed values (minimum to maximum)
| Figure 1. Mean Florfenicol Plasma Concentration versus Time Following a Single Subcutaneous Injection of NUFLOR GOLD™ at a Dose Rate of 40 mg Florfenico/kg Body Weight in Feeder Calves (Mean ± Standard Error of the Mean) |
Florfenicol is a synthetic, broad-spectrum antibiotic active against many Gram-negative and Gram-positive bacteria isolated from domestic animals. It acts by binding to the 50S ribosomal subunit and inhibiting bacterial protein synthesis. Florfenicol is generally considered a bacteriostatic drug, but it exhibits bactericidal activity against certain bacterial species. In vitro studies demonstrate that florfenicol is active against the BRD pathogens M. haemolytica, P. multocida, H. somni, and M. bovis and that florfenicol exhibits bactericidal activity against strains of M. haemolytica and H. somni.
The minimum inhibitory concentrations (MICs) of florfenicol were determined for BRD isolates obtained from calves enrolled in BRD field studies in the U.S. in 2006 using methods recommended by the Clinical and Laboratory Standards Institute (M31-A2). Isolates were obtained from pre-treatment nasal swabs from all calves enrolled at all four sites, post-treatment nasal swabs from treatment failures in the NUFLOR GOLD Injectable Solution and saline control treatment groups at three sites, and lung tissue from one calf that died in the saline control treatment group. The results are shown below in Table 2.
| Indicated pathogens | Year of isolation | No. of isolates | MIC50
†
(µg/mL) | MIC90
†
(µg/mL) | MIC range (µg/mL) |
|---|---|---|---|---|---|
| Mannheimia haemolytica | 2006 | 158 | 1.0 | 1.0 | 0.5 to 32 |
| Pasteurella multocida | 2006 | 103 | 0.5 | 0.5 | ≤ 0.125 to 16 |
| Histophilus somni | 2006 | 85 | ≤ 0.125 | ≤ 0.125 | ≤ 0.125 to 0.25 |
A target animal safety study was conducted to evaluate the effects of NUFLOR GOLD™ when administered to feeder cattle by subcutaneous injection at 1X, 3X, or 5X the labeled dose for three consecutive days (3X the labeled duration). Decreased feed consumption (inappetence), decreased water consumption, and injection site swelling were observed in the 1X, 3X, and 5X groups.
A separate injection site study conducted in cattle demonstrated that NUFLOR GOLD™ may induce a transient local reaction in the subcutaneous tissue and underlying muscle tissue.
Store between 2°-30°C (36°-86°F). Use within 28 days of first use. Refrigeration is not required. The solution is light yellow to straw colored. Color does not affect potency.
NUFLOR GOLD™ is packaged in 100 mL (NDC 0061-5327-01), 250 mL (NDC 0061-5327-02), and 500 mL (NDC 0061-5327-03) glass sterile multiple-dose vials.
Made in Germany
Intervet Inc., Roseland, NJ 07068
© 2009, Intervet Inc.
All rights reserved.
B-31331005 7/09
F-31331005
NADA 141-265, Approved by FDA.
NuflorGOLD™
(florfenicol)
Injectable Solution, An Antimicrobial
For subcutaneous use in beef and non-lactating dairy
cattle only
Not for use in female dairy cattle 20 months of age or
older or in calves to be processed for veal
Caution: Federal law restricts this drug to use by or on
the order of a licensed veterinarian
NADA 141-265, Approved by FDA
Intervet
Schering-Plough Animal Health
NDC 0061-5327-01
100 mL Multiple Dose Vial • 300 mg/mL • Sterile
NuflorGOLD™
(florfenicol)
Injectable Solution,
An Antimicrobial
Caution: Federal law restricts this drug to use by or
on the order of a licensed veterinarian
NADA 141-265, Approved by FDA
NDC 0061-5327-01
Intervet
Schering-Plough Animal Health
100 mL Multiple Dose Vial • 300 mg/mL • Sterile
NuflorGOLD™
(florfenicol)
Injectable Solution, An Antimicrobial
For subcutaneous use in beef and non-lactating dairy
cattle only
Not for use in female dairy cattle 20 months of age or
older or in calves to be processed for veal
Caution: Federal law restricts this drug to use by
or on the order of a licensed veterinarian
NADA 141-265, Approved by FDA
Intervet
Schering-Plough Animal Health
NDC 0061-5327-02
250 mL Multiple Dose Vial • 300 mg/mL • Sterile
NuflorGOLD™
(florfenicol)
Injectable Solution, An Antimicrobial
For subcutaneous use in beef and non-lactating dairy
cattle only
Not for use in female dairy cattle 20 months of age or older
or in calves to be processed for veal
Caution: Federal law restricts this drug to use by
or on the order of a licensed veterinarian
NADA 141-265, Approved by FDA
Intervet
Schering-Plough Animal Health
NDC 0061-5327-03
500 mL Multiple Dose Vial • 300 mg/mL • Sterile
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Florfenicol | ACTIVE INGREDIENT | 9J97307Y1H | 1 | |
| Florfenicol | ACTIVE MOIETY | 9J97307Y1H | 1 | |
| Triacetin | INACTIVE INGREDIENT | XHX3C3X673 | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 0061-5327 | 0061-5327-01, 0061-5327-02, 0061-5327-03 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| Florfenicol | 9J97307Y1H | ACTIB |
| Triacetin | XHX3C3X673 | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| Triacetin | TRIACETIN | XHX3C3X673 | TABLET, EXTENDED RELEASE / ORAL | 26 mg | ||
| Triacetin | TRIACETIN | XHX3C3X673 | POWDER, FOR SUSPENSION / ORAL | 12 mg | ||
| Triacetin | TRIACETIN | XHX3C3X673 | SUSPENSION, EXTENDED RELEASE / ORAL | 4 mg | ||
| Triacetin | TRIACETIN | XHX3C3X673 | CAPSULE, EXTENDED RELEASE / ORAL | 467 mg | ||
| Triacetin | TRIACETIN | XHX3C3X673 | TABLET, COATED / ORAL | 1 mg | ||
| Triacetin | TRIACETIN | XHX3C3X673 | SUSPENSION / ORAL | 7 mg | ||
| Triacetin | TRIACETIN | XHX3C3X673 | CAPSULE / ORAL | 13 mg | ||
| Triacetin | TRIACETIN | XHX3C3X673 | CAPSULE, DELAYED RELEASE / ORAL | 5.1 mg | ||
| Triacetin | TRIACETIN | XHX3C3X673 | TABLET / ORAL | 208 mg | ||
| Triacetin | TRIACETIN | XHX3C3X673 | TABLET, CHEWABLE, EXTENDED RELEASE / ORAL | 2 mg | ||
| Triacetin | TRIACETIN | XHX3C3X673 | TABLET, DELAYED RELEASE / ORAL | 23 mg | ||
| Triacetin | TRIACETIN | XHX3C3X673 | CONCENTRATE / ORAL | 250 mg | ||
| Triacetin | TRIACETIN | XHX3C3X673 | SYSTEM / TRANSDERMAL | 22.1 mg | ||
| Triacetin | TRIACETIN | XHX3C3X673 | TABLET, FILM COATED / ORAL | 15.12 mg |
Adverse event summaries are temporarily unavailable. Other product information remains available.